Compare Emerson Electric Co. (EMR) vs Organon & Co. Common Stock (OGN) Price & Performance

Emerson Electric (EMR) trades at $161.08, down 0.85% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a 13.83% net income margin and consistent earnings beats in recent quarters. Revenue is projected to grow to $18.6B in 2026, and analysts maintain a consensus buy rating with a $165.90 price target, suggesting modest upside. A dividend of $0.56 per share is scheduled for payment in September 2026.

EMR presents a favorable outlook supported by earnings momentum and analyst optimism, though valuation multiples like a P/E of 35.78 are elevated. Key risks include competitive pressures and macroeconomic sensitivity. The stock's proximity to resistance at $164 may prompt near-term consolidation, but fundamental strength supports long-term growth potential.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.